Adze Biotechnology Pipeline

Our platform of intravenously and intratumorally deliverable oncolytic immunotherapies enables us to pursue multiple indications across broad patient populations.

Adze Oncolytic Immunotherapies stimulate and recruit innate and adaptive immune responses to cancer.

Projected Cancer Deaths - 2022

Despite recent advances in cancer therapeutics, severe unmet needs exist for patients world-wide, and many cancer patients still die each year. 

Adze oncolytic immunotherapies have the potential to treat hundreds of thousands of these patients.